<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443805</url>
  </required_header>
  <id_info>
    <org_study_id>SL75.14</org_study_id>
    <nct_id>NCT02443805</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of 12 months of treatment
      with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents
      with HDM-associated allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Combined Score</measure>
    <time_frame>12 months</time_frame>
    <description>The daily TCS is the sum of the patient's daily Rhinitis Total Symptom Score and daily Rescue Medication Score and will be assessed during 4 weeks at the end of a 12-month treatment duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability evaluated on adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1740</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>300 IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 IR tablet of HDM Allergen Extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>300 IR</intervention_name>
    <description>300 IR tablet of HDM Allergen Extracts</description>
    <arm_group_label>300 IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients with HDM-associated allergic rhinitis (AR) for at least 1 year

          -  Patients sensitized to D. pteronyssinus (D. pte) and/or D. farinae (D. far) defined
             on skin prick test and HDM-specific serum IgE

        Main Exclusion Criteria:

          -  A history of rhinitis, rhinoconjunctivitis or asthma to allergens other than HDM,
             likely to result in rhinitis symptoms during the evaluation periods

          -  Partly controlled or uncontrolled asthma

          -  Controlled asthma requiring controller treatment(s) consistent with GINA 2014
             treatment Steps 3 to 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Arnaud de Villeneuve, Montpellier, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Casale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South of Florida, Tampa, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine Le Gall</last_name>
    <phone>+33 1 55 59 25 56</phone>
    <email>mlegall@stallergenes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Rodriguez</last_name>
    <phone>+33 1 55 59 28 03</phone>
    <email>prodriguez@stallergenes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Casale, MD</last_name>
      <email>tbcasale@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Demoly, MD</last_name>
      <phone>+33 (0)4 67 04 20 20</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>April 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
